Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
grade F 80.52 -0.41% -0.33
ABBV closed down 0.41 percent on Tuesday, February 19, 2019, on 78 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ABBV trend table...

Date Alert Name Type % Chg
Feb 19 20 DMA Resistance Bearish 0.00%
Feb 19 Weak + Overbought Other 0.00%
Feb 19 Inside Day Range Contraction 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 15 20 DMA Resistance Bearish -0.41%
Feb 15 Stochastic Reached Overbought Strength -0.41%
Feb 15 Weak + Overbought Other -0.41%
Feb 15 Overbought Stochastic Strength -0.41%
Feb 14 Narrow Range Bar Range Contraction 0.00%
Feb 14 NR7 Range Contraction 0.00%

Older signals for ABBV ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Chemistry Chemical Compounds Organic Compounds Pharmaceutical Products Autoimmune Diseases Prostate Cancer Chloroarenes Cardiology Cholesterol Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Lipoproteins Secondary Hyperparathyroidism Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Research Based Biopharmaceutical Testosterone Replacement Therapy
Is ABBV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 122.0
52 Week Low 75.77
Average Volume 7,198,267
200-Day Moving Average 91.8385
50-Day Moving Average 84.8564
20-Day Moving Average 80.8255
10-Day Moving Average 79.999
Average True Range 1.9866
ADX 21.13
+DI 22.0768
-DI 29.1323
Chandelier Exit (Long, 3 ATRs ) 83.83020000000001
Chandelier Exit (Short, 3 ATRs ) 81.7298
Upper Bollinger Band 86.9782
Lower Bollinger Band 74.6728
Percent B (%b) 0.48
BandWidth 15.224651
MACD Line -1.4493
MACD Signal Line -1.7948
MACD Histogram 0.3455
Fundamentals Value
Market Cap 128.36 Billion
Num Shares 1.59 Billion
EPS 4.07
Price-to-Earnings (P/E) Ratio 19.78
Price-to-Sales 5.35
Price-to-Book 23.76
PEG Ratio 1.00
Dividend 2.56
Dividend Yield 3.18%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 82.46
Resistance 3 (R3) 82.57 82.05 82.13
Resistance 2 (R2) 82.05 81.55 81.99 82.02
Resistance 1 (R1) 81.28 81.25 81.67 81.17 81.92
Pivot Point 80.76 80.76 80.95 80.70 80.76
Support 1 (S1) 79.99 80.26 80.38 79.88 79.12
Support 2 (S2) 79.47 79.96 79.41 79.02
Support 3 (S3) 78.70 79.47 78.91
Support 4 (S4) 78.59